METHYLIN ER Drug Patent Profile
Which patents cover Methylin Er, and when can generic versions of Methylin Er launch?
Methylin Er is a drug marketed by Specgx Llc and is included in one NDA.
The generic ingredient in METHYLIN ER is methylphenidate hydrochloride. There is one drug master file entry for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Methylin Er
A generic version of METHYLIN ER was approved as methylphenidate hydrochloride by SPECGX LLC on November 27th, 1998.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for METHYLIN ER?
- What are the global sales for METHYLIN ER?
- What is Average Wholesale Price for METHYLIN ER?
Summary for METHYLIN ER
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 53 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,374 |
| DailyMed Link: | METHYLIN ER at DailyMed |
Recent Clinical Trials for METHYLIN ER
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Nicoleta Stoicea | Phase 1 |
| Boston Children's Hospital | Phase 1 |
| Dana-Farber Cancer Institute | Phase 1 |
Pharmacology for METHYLIN ER
| Drug Class | Central Nervous System Stimulant |
| Physiological Effect | Central Nervous System Stimulation |
US Patents and Regulatory Information for METHYLIN ER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specgx Llc | METHYLIN ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 075629-001 | May 9, 2000 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Specgx Llc | METHYLIN ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 075629-002 | May 9, 2000 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
